View the latest news and SEC filings
Scroll to
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
September 14, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
|
|
August 27, 2020 |
EFFECT |
EFFECT |
Other |
|
|
August 27, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
|
|
August 25, 2020 |
CORRESP |
CORRESP |
Other |
|
|
August 25, 2020 |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A |
Registration Statements |
|
|
August 25, 2020 |
Amendment to a previously filed 6-K |
6-K/A |
Current Reports |
|
|
August 24, 2020 |
UPLOAD |
UPLOAD |
Other |
|
|
August 20, 2020 |
Securities offered to employees pursuant to employee benefit plans |
S-8 |
Registration Statements |
|
|
August 19, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
